103 CARNEGIE CENTER, PRINCETON, NJ
Market cap: $34.2M (10/24/2024)
Price: $3.37
Announces Second Quarter 2026 Financial Results, Provides Business Update
Secures Approximately $4.0 Million through Common Warrant Exercises Following Acceptance of New Drug Application for GTx-104 for formal FDA Review.
Granted Sixth U.S. Patent Covering I.V. Dosing Regimen for GTx-104
Shareholder votes
FDA Accepts Grace Therapeutics' GTx-104 for Review, Targets April 23, 2026 for aSAH Drug Decision
Grace Therapeutics Q1 2026 Results and GTx-104 NDA Submission for aSAH Treatment
Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Announces 2025 Fiscal Year-End Results, Provides Business Update Held Type C meeting with FDA on Planned New Drug Application (NDA) Submission, Including Clinical, Non-clinical, and Chemistry, Manufacturing, and Control (CMC) Requirements NDA On Track for Submission to FDA in First Half of Calendar 2025 NDA to be Supported by Data from Phase 3 STRIVE-ON Safety Trial, which Met Prima
Amended Quarterly Report
Q2
Q1
FY 2025
Q3
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Notice of Exempt Offering of Securities
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Additional Proxy Materials
Definitive Proxy Statement
Amended Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
S-8 POS